|
Press Releases |
|
 |
|
Wednesday, July 31, 2024 |
|
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024 |
Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI), an anti-amyloid beta (Abeta) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2024, held in Philadelphia, and virtually. more info >> |
|
Monday, July 29, 2024 |
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union |
Eisai Co., Ltd. and Biogen Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the Marketing Authorization Approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab as treatment for early AD (mild cognitive impairment due to Alzheimer?s disease (AD) and mild AD). more info >> |
|
Thursday, July 25, 2024 |
|
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration |
Eisai Co., Ltd. and EcoNaviSta Inc. announced today that they have entered into a business alliance agreement and commenced collaboration with the aim of building an ecosystem in the area of dementia, which is a pressing matter in Japan's super-aging society. more info >> |
|
Tuesday, July 23, 2024 |
|
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024 |
The conference will be held in Philadelphia and virtually from July 28 to August 1, 2024. Eisai will present data and research in four (4) oral and 15 poster presentations at the meeting and will host two (2) sessions on lecanemab. more info >> |
|
Friday, July 12, 2024 |
|
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel |
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab) has been approved in Israel as a treatment of Alzheimer's disease (AD). more info >> |
|
Thursday, July 11, 2024 |
|
LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Hong Kong |
Eisai Co., Ltd. and Biogen Inc. announced today that the Department of Health in HongKong has approved humanized anti-soluble aggregated amyloid-beta (Abeta;) monoclonal antibody "LEQEMBI" (brand name in Hong Kong: generic name: lecanemab) for treatment of Alzheimer's disease (AD). more info >> |
|
Tuesday, July 2, 2024 |
|
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) |
Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin (FZEC), formerly known as MORAb-202, a folate receptor alpha (FRα)-targeting antibody drug conjugate (ADC) due to ongoing portfolio prioritization efforts within Bristol Myers Squibb. more info >> |
|
Friday, June 28, 2024 |
|
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China |
China is the third country to launch LEQEMBI following the United States and Japan. more info >> |
|
Friday, June 21, 2024 |
|
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City |
Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo City, Tokyo, which the company has been commissioned to conduct in order to raise awareness of dementia and promote early detection, and will continue the commission for this project in FY2024. more info >> |
|
Monday, June 10, 2024 |
|
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI) intravenous (IV) maintenance dosing. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
Ta Yang Group Holdings Limited Announcing AI Transformation Blueprint
Aug 22, 2025 19:21 HKT/SGT
|
|
|
CaoCao Inc. (2643.HK) Added to Hang Seng Composite Index, Set to Join Hong Kong Stock Connect on Sept 8
Aug 22, 2025 18:51 HKT/SGT
|
|
|
CITIC Resources Deepens Dual Driver Development Strategy of "Investment + Trading"
Aug 22, 2025 18:28 HKT/SGT
|
|
|
Everbright Grand China Achieved Revenue of RMB24.5 Million in 2025 1H
Aug 22, 2025 13:26 HKT/SGT
|
|
|
CHINA INTERNATIONAL DEVELOPMENT CORPORATION LIMITED ANNOUNCES STRATEGIC ACQUISITION OF 20% STAKE IN NVT
Aug 22, 2025 08:22 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Successfully Carries Out Space Protein Crystallization Experiments
Aug 22, 2025 3:00 JST
|
|
|
Asia's CX Leaders Are Aligning Strategy Around AI, Efficiency, and Workforce Engagement: Key Insights from Customer Experience Live Show Asia 2025
Aug 21, 2025 22:00 HKT/SGT
|
|
|
NEC digital technologies to empower small-scale producers in Africa in partnership with IFAD
Aug 21, 2025 20:32 JST
|
|
|
Graphene Manufacturing Group Ltd. Announces Upsize of Bought Deal Public Offering for Gross Proceeds of C$6 Million
Aug 21, 2025 19:29 HKT/SGT
|
|
|
Sharp Corporation and Sharp Energy Solutions Corporation Sign Memorandum of Understanding with Mitsui O.S.K. Lines, and AAR Japan for Donation of Solar Modules to Kenya
Aug 21, 2025 20:15 JST
|
|
|
Aiming to Build Battery Ecosystem, Toyota and Mazda Start Tests of Energy Storage System Using Electrified Vehicle Batteries
Aug 21, 2025 19:50 JST
|
|
|
NEC signs Memorandum of Cooperation with the Senegalese government, CFPT-SJ, JICA, and four Japan-based companies for vocational training in Senegal
Aug 21, 2025 19:27 JST
|
|
|
Genes Tech Group Announces 2025 Interim Results, Total revenue increased by 9.40% YoY to approximately NTD585.31 million
Aug 21, 2025 18:22 HKT/SGT
|
|
|
Sharp Corporation and Sharp Energy Solutions Corporation Sign Memorandum of Understanding with Mitsui O.S.K. Lines, and IOM to Advance Cooperation through Renewable Energy
Aug 21, 2025 19:07 JST
|
|
|
Lepu Biopharma (2157.HK) announces 2025 interim results
Aug 21, 2025 14:38 HKT/SGT
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|